Our laboratory provides state-of-the-art testing for preclinical ocular toxicity. It is vitally important to test drugs early on for ocular toxicity before major investment has been made in the development process, as this could have serious repercussions for patients and researchers if left undetected.
STZ OcuTox offers unique expertise and services relating to all aspects of preclinical testing of events in the eye. Read more about our profile:
As a scientist and internationally acknowledged expert he is specialized in the pathology of the retinal pigment epithelium, a key cell layer for pathogenic events in AMD. The purpose of his unit is the discovery of candidates for ophthalmological drug development and also the support of pharmaceutical entities in toxicological and efficacy studies with respect to events in the eye.
Dr. Schraermeyer also heads the Section of Experimental Vitroretinal Surgery at the Centre for Ophthalmology, University Eye Hospital in Tübingen.
Dr. Schraermeyer holds a degree in cellular biology and a PhD from the University of Düsseldorf.